Device Trial Radar · NCT03029299
Implementation Assessment and Clinical Utility of the FilmArray® Respiratory Panel (RP) EZ in a CLIA-waived Setting
Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Apr 4, 2017
Primary completion
Sep 15, 2017
Study completion Sep 15, 2017
Sponsor
- Lead sponsor
- BioFire Diagnostics, LLCNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- University of California, Los Angeles
- First posted
- Jan 24, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BioFire Diagnostics, LLC (BioFire; a bioMerieux company), has developed a multiplexed molecular-based in vitro diagnostic platform for infectious disease testing known as the FilmArray. The FilmArray Respiratory Panel (RP) EZ is a test designed for use with the FilmArray 2.0 EZ Configuration instrument that identifies common bacterial and viral microorganisms associated with respiratory tract infections from a nasopharyngeal swab (NPS) specimen collected in viral transport media (VTM). The RP EZ was granted CLIA-waived classification by the FDA in October 2016 and is the first highly-multiplexed molecular test to receive this designation. The purpose of this study is to measure patient outcomes following implementation of the RP EZ test and to also gather data about physician office workflow and user interactions with the device. These data will be used to understand how the adoption of such tests may influence patient care in the CLIA-waived setting.
Conditions
- Respiratory Tract Infections
Interventions
FilmArray RP EZDevice
Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time duration from initial visit to receipt of appropriate therapyTime frame: through study completion, an average of one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.